🟢 Cybin is trading 11% up today after appointing former Intra-Cellular president Michael Halstead as CEO

Cybin is trading 11% up at $8.88 following the announcement of Michael Halstead as its new CEO.

• Halstead previously served as the president of Intra-Cellular Therapies and was a key architect of a $14.6 billion deal with Johnson & Johnson.
• Investors are reacting to Halstead's proven track record in developing and commercializing CAPLYTA and his experience in executing major strategic transactions.
• The leadership change has significantly bolstered market confidence in the company's long-term growth and execution outlook.